Evidence map›Paper›PMID 37295300›Full record

ArticleSeminars in arthritis and rheumatism2023

Offspring neurodevelopmental outcomes born to parents with chronic inflammatory arthritis using antirheumatic therapies: A scoping review.

Eugenia Y Chock, Sovit Dahal, Alyssa A Grimshaw, Lisa Suter, Zeyan Liew, David Felson

Open access · greenAbstract readScoping Review
In one paragraph

Article in Seminars in arthritis and rheumatism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 1 country.

Eugenia Y ChockSection of Rheumatology, Yale School of Medicine, New Haven, CT, USA. Electronic address: yupeieugenia.chock@yale.edu.
Sovit DahalDepartment of Internal Medicine, Griffin Hospital, Derby, CT, USA.
Alyssa A GrimshawHarvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, CT, USA.
Lisa SuterSection of Rheumatology, Yale School of Medicine, New Haven, CT, USA; Veterans Health Administration, West, Haven, CT, USA.
Zeyan LiewDepartment of Environmental Health Sciences and Yale Center for Perinatal, Pediatric, and Environmental Epidemiology, Yale School of Public Health, New Haven, CT, USA.
David FelsonSection of Rheumatology, Yale School of Medicine, New Haven, CT, USA; Section of Rheumatology, Boston University School of Medicine, Boston, MA, USA and Section of Rheumatology, Yale School of Medicine, New Haven, CT, USA.
Boston University · USGriffin Hospital · USProvidence Center · USUnited States Department of Veterans Affairs · USYale Cancer Center · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Research and Evaluation Support Core Unit (RESCU Core)P30AR072571 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI TUHINA NEOGI · 2019 to 2026
$6.9M
NCATS NIH HHS UL1 TR001863NIAMS NIH HHS P30 AR072571
6 · The paper itself

Abstract

introductionMost women with rheumatic diseases discontinue antirheumatic therapies in anticipation of, or during pregnancy due to concerns around medication safety and fetal wellbeing.

objectiveWe performed a scoping review of available evidence investigating the risks of adverse offspring neurodevelopmental outcomes amongst parents with chronic inflammatory arthritis, taking antirheumatic therapies during conception or pregnancy.

methodsWe designed a scoping review protocol and search strategy a priori in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We performed an exhaustive search in Cochrane Library, Embase, Google Scholar, Medline, and Web of Science for relevant literature in January 2023. Articles needed to include offspring neurodevelopmental outcomes born to parents with CIA who took antirheumatic therapies during conception or pregnancy. Independent reviewers extracted data from eligible articles using a standard abstraction tool and performed critical appraisal of study quality.

resultsSix studies were included for full data abstraction. Use of Nonsteroidal Anti-inflammatory Drugs, Tumor Necrosis Factor Alpha inhibitors, and exposure to methotrexate during early first trimester of pregnancy did not seem to increase risk for adverse offspring neurodevelopmental outcomes. Corticosteroid use during pregnancy seemed to pose an increased risk for attention deficit hyperactive disorders in offspring.

conclusionUse of some antirheumatic therapies during pregnancy may not be associated with adverse offspring neurodevelopmental outcomes. Further investigations are needed to elucidate if other confounding factors affect long term offspring health outcomes born to parents with chronic inflammatory arthritis.

Indexed as

Antirheumatic AgentsArthritisAnti-Inflammatory Agents, Non-SteroidalFemaleHumansMethotrexateParentsPregnancyAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsMethotrexateAntirheumatic MedicationsChronic Inflammatory ArthritisOffspring OutcomesPregnancy

Identifiers

PMID37295300
PMCPMC10521166
OpenAlexW4379112967

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.